TFC Financial Management Inc. Sells 82 Shares of Becton, Dickinson and Company (NYSE:BDX)

TFC Financial Management Inc. trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 9.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 789 shares of the medical instruments supplier’s stock after selling 82 shares during the period. TFC Financial Management Inc.’s holdings in Becton, Dickinson and Company were worth $179,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Tompkins Financial Corp lifted its stake in Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 46 shares during the last quarter. Radnor Capital Management LLC grew its position in Becton, Dickinson and Company by 1.7% during the third quarter. Radnor Capital Management LLC now owns 2,937 shares of the medical instruments supplier’s stock worth $708,000 after buying an additional 48 shares in the last quarter. Wesbanco Bank Inc. boosted its holdings in shares of Becton, Dickinson and Company by 1.9% in the 4th quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock valued at $580,000 after purchasing an additional 48 shares in the last quarter. Umpqua Bank boosted its holdings in shares of Becton, Dickinson and Company by 1.8% in the 3rd quarter. Umpqua Bank now owns 2,738 shares of the medical instruments supplier’s stock valued at $660,000 after purchasing an additional 49 shares in the last quarter. Finally, Americana Partners LLC lifted its stake in shares of Becton, Dickinson and Company by 3.5% in the 3rd quarter. Americana Partners LLC now owns 1,468 shares of the medical instruments supplier’s stock valued at $354,000 after acquiring an additional 50 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 500 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the sale, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. This represents a 8.01 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Shana Carol Neal sold 788 shares of the stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $185,180.00. Following the completion of the sale, the executive vice president now directly owns 16,201 shares in the company, valued at approximately $3,807,235. This represents a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 10,544 shares of company stock valued at $2,370,309. 0.36% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday. Piper Sandler upped their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $283.00.

Becton, Dickinson and Company Trading Down 1.7 %

NYSE BDX opened at $225.72 on Thursday. The company has a quick ratio of 0.74, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. The firm has a market cap of $65.46 billion, a PE ratio of 37.50, a price-to-earnings-growth ratio of 1.65 and a beta of 0.40. The company has a 50 day moving average price of $232.36 and a 200 day moving average price of $233.94. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 14.41 EPS for the current fiscal year.

Becton, Dickinson and Company announced that its board has initiated a stock buyback program on Tuesday, January 28th that permits the company to buyback 10,000,000 outstanding shares. This buyback authorization permits the medical instruments supplier to purchase shares of its stock through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.84%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 69.10%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.